Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

ED50

Brian J. Kenny  1 , Charles V. Preuss  2 , Arthur S. McPhee
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

ED50

Brian J. Kenny et al.
Free Books & Documents

Excerpt

The ED50 is the dose of a medication that produces a specific effect in 50% of the population that has been administered that dose. This metric can be used clinically by clinicians for a particular drug effect. However, depending on the risk-benefit analysis, clinicians may use a different dosage for their intended outcome. The toxic dose in 50% of the population is called TD50; the ED50 should be much less than the TD50, as this would indicate an effective medication at a lower dose. The ED50 for a particular medication is derived from a dose-response curve, in which the ED50 is at the dosage (x-axis), where there is 50% of the desired response (y-axis).

PubMed Disclaimer

Conflict of interest statement

Disclosure: Brian Kenny declares no relevant financial relationships with ineligible companies.

Disclosure: Charles Preuss declares no relevant financial relationships with ineligible companies.

Disclosure: Arthur McPhee declares no relevant financial relationships with ineligible companies.

References

    1. Dimmitt S, Stampfer H, Martin JH. When less is more - efficacy with less toxicity at the ED50. Br J Clin Pharmacol. 2017 Jul;83(7):1365-1368. - PMC - PubMed
    1. Martin JH, Fay MF. Surrogate end-points in clinical practice: are we providing worse care? Intern Med J. 2010 Jun;40(6):395-8. - PubMed
    1. Stampfer HG, Gabb GM, Dimmitt SB. Why maximum tolerated dose? Br J Clin Pharmacol. 2019 Oct;85(10):2213-2217. - PMC - PubMed
    1. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA, HEAAL Investigators Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009 Nov 28;374(9704):1840-8. - PubMed
    1. Mouton JP, Mehta U, Parrish AG, Wilson DP, Stewart A, Njuguna CW, Kramer N, Maartens G, Blockman M, Cohen K. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey. Br J Clin Pharmacol. 2015 Oct;80(4):818-26. - PMC - PubMed

Publication types

LinkOut - more resources